Healthy Stock Picks (@Healthstockpick) header
Healthy Stock Picks (@Healthstockpick) profile picture

20 years of investing. Now covering the Healthcare sector, predominantly micro to mid-caps. All my writing is free, no pay-walls.

Global
Joined February 2024
Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)
Healthcare portfolio out-performing my wider portfolio, mostly thanks to Modern Dental and more recently Envista, still in total with several stocks in serious drawdowns I'm up less than 1% YTD. As you can see Medtech sector has been brutal in 2026, down 6%.
1
1
14
3,402
Healthy Stock Picks retweeted
24
91
4
2,819
98,883
What started for me with an email to $OSSD CEO asking who their largest competitor was, I started to look at $KURN Over time I realized Kuros is winning I sold my OSSD shares and held KURN. I think by now we can already conclude the race as over, perhaps $BONEX can put up a fight
1
1
10
1,455
Will be hard for $BONEX.ST to keep up, revenue:
2
294
Healthy Stock Picks retweeted
A few charts on China real estate prices, rents, sales. For tier 1 cities, we are now back to 2016 prices, 10 year roundtrip (and counting). Comparison: --In the US, prices bottomed in 2012, back to 2004 levels, 8 years roundtrip. --In Europe, bubble chad places like Spain, prices bottomed in 2015 back to 2002 levels, 13 years. Time to start bottoming? Or 3 more years to go? Who knows. HK turned already last year. Funny (or sad): --Spain, 10 years after bottoming, is now on the opposite side, complaining about high prices (fair complain, they are high vs salaries). The eternal pendulum. --Those that complain ask for more new housing to bring down prices. They don't have memory of what made prices come down in 2007, for how long, and why nobody could buy for the next 10 years despite lower prices. Careful what you wish for. --In China prices only started to come down when financing to developers was cut and they stopped building houses. --People tell you supply/demand charts work. The craving to explain the world with two variables. They don't. Only at extremes. Demand drives the market, not supply. Demand depends on expectations and FOMO, not on families calculating how new build inventories will impact prices. Same with share prices. --aaaanyway. Same story, every time.
8
9
1
75
7,700
After getting much more insight into the working hours and night shifts doctors are pulling, I have a lot of feelings on this topic. 1. It is not OK that doctors have to work 30h+ hour shifts with no to little sleep. 2. Is not OK to be treated for something serious by said doctor
" I am so out of time." A surgeons warning.
2
5
1,191
Why is this normalized in most countries? I really don’t understand, educate more doctors reduce working hours and wages, create work life balance, which countries have actually implemented this?
1
232
Interesting times for contrarians, I have loaded up on a few already, one already doubled from the bottom, volatility is insanely high in something that should be stable predictable non/low-cyclical business
Large Cap Med-Tech trades at its lowest multiple in over a decade. It also trades at its lowest relative P/E to S&P 500 since the Dot Com Bubble. Wild times in MedTech land.
3
1
11
2,898
As we can see these dislocations only happen when the market gets totally sucked into a hype in another sector like 1998-2000 and the past two years with AI
2
308
Replying to @leevalueroach
What about your job?
12
1
133
4,048
Healthy Stock Picks retweeted
I was having dinner last night with a friend working in the chicken industry and I learned something that blew my mind. Where do chicken farmers get their chickens? Most of us would say "from their existing chickens obviously, they breed and lay eggs." That's what I thought too, but turns out I was dead wrong. The reality is that the immense majority of meat chicken farmers in the world get their chickens from one of 2 companies: Cobb-Vantress, owned by Tyson Foods, or Aviagen, controlled by Germany's EW Group (the Wesjohann family). They have a concept specific to the industry called grandparent stock: what you buy from these 2 companies is - essentially - a bunch of chickens with planned obsolescence. The way it works is that each company keeps "pure" bloodlines on its own farms. Let's label them A, B, C and D. Those are the crown jewels - these companies' IP - and they never leave the building. What they sell you are the "grandparents": chicks from those four lines, but each line in only one sex. You get A roosters but no A hens, B hens but no B roosters, C roosters but no C hens, D hens but no D roosters. Which means you can never breed more A, B, C or D birds yourself. What you can do is cross them. A roosters with B hens give you the fathers, C roosters with D hens give you the mothers - these are the "parents". The parents then give you the chickens that actually end up on our plates, slaughtered at around 6 weeks. And that's the end of the road. If you tried breeding those chickens, their chicks would be a complete genetic lottery: still chickens, sure, but without the genetic properties that make them commercially viable. They'd grow slower and less evenly, you'd have to sell them for way more than your competitors, and your business would be dead. So you have to go back to Cobb or Aviagen for new grandparents. Forever. Why buy grandparents at all, and raise 2 generations just to sell the third? The answer is scale. If you buy say 100 grandparents, each of them gives you around 50 parents, and each parent hen then gives you around 150 chicks: from those 100 grandparents, you have yourself some 600,000 chickens whose meat you can sell. It makes no sense for these 2 companies to sell the final chickens directly. They'd have to hatch tens of billions of chicks a year and ship them all over the world. Much easier to simply sell the grandparents and let farmers do the multiplying and pay for the farms, the feed and the labor. And, you knew this was coming, there is also a China angle here: as you can imagine, China isn't too pleased to be dependent on foreign companies for such a basic food item as chicken. So China did what China does best: long-term planning. The Ministry of Agriculture and Rural Affairs launched a plan for "national broiler genetic improvement" (2021-2035), which aims for domestically bred breeds to make up at least 60% of the domestic market by 2035 (globaltimes.cn/page/202307/1…). And, of course, they're ahead of the plan. As of 2025, homegrown breeds held more than 30% of the market: halfway to the 2035 goal in just four years (agripost.cn/2026/08/17/china…). Can you escape all this as a consumer? Sure, you can buy organic or Label Rouge chicken, from slower-growing breeds raised for at least 81 days instead of 6 weeks, for two to three times the price. Except, plot twist: the genetics behind most of those slow-growing birds come from a French company called Hubbard... which has belonged to Aviagen since 2018 (euromeatnews.com/aviagen-ann…)😅 And even if you could truly escape, you wouldn't want everyone to: we'd need vast new swathes of farmland, both for the chickens and their feed. Ironically, advocating for organic free-range chicken for everyone is one of the worst positions one can take for the planet's resources. If you want to minimize your environmental footprint, the counterintuitive answer is to buy the cheapest supermarket chicken - or eat less meat, of course. As my friend was saying last night, you may not like the way this industry works but, at the end of the day, it's what puts affordable protein on the plates of billions of people, using proportionally fewer resources than any other way of raising chicken.
214
1,521
227
6,341
486,927
For various reasons, AI, life, mood I have not posted for a year, but now Im back with an idea, hope you enjoy it, as always no paywalls, link in my profile - Ak Medical $1789.HK
3
34
2,625
Many good points on HK and inequality. Sweden where I come from is very equal and few people has the need to show wealth through luxury goods
Americans take note 👀 The gambling junkies are expanding EVERYWHERE as your currency becomes shit everything downstream will go to shit
2
705
Coming to Hong Kong before year end?
I CALLED IT. It's happening y'all. The singapore gov has launched a pilot programme for a gov-run dating service. Looks like the pilot is currently restricted to just government workers for now.
1
499
Healthy Stock Picks retweeted
I’m not complaining either… this madness has helped deliver my best PA year literally ever. Gotta say though, this turned into a bubble pretty quick. Crazy that I could happen given what rates did over same period. Fully out of all my AI drug disco correlated holdings. Plan to at least stay in the production tools and ride the beta / fundamental accel next year but I am considering some spicy next steps. Not saying said bubble it can’t continue to inflate, but I’m seeing total cyclical price action in low-quality names, just like we saw in the 1H bottleneck trade. Problem is, you don’t really get a “cycle” in fundamentals here. This is no “bottleneck” in the trade. We are pricing in a much bigger upcycle than we will actually get. What is getting missed is 1) the extent to which life sciences R&D as an industry moves slowly, 2) why it can’t speed beyond a certain point, and 3) the profitability upside potential for this space being much lower vs real cyclicals. Life science R&D has a muted, long-term underlying cycle where only volume demand moves, not price (in fact, tools pricing for most categories rises modestly every year). AI drug discovery will be additive to this in some ways, and negative in others. The industry R&D budget isn’t going to explode upward. I can re organize slowly. But pricing for a product or service doesn’t double or triple because there’s a “bottleneck”. In an up cycle, demand surprises by a few points vs historical means. AI drug discovery can’t change this overnight, and lab automation has been around for longer than most realize. I’ll elaborate on the above another time, but IMO the strangest part of all this is that the genomics testing companies like $ntra $PSNL etc. are being conflated with the theme when they have little to do with it. They’re just awesome in their own right (which they have been for a while). Some of this is $MRNA $GRAL news but both are also being over extrapolated to some extent. I expect that this lil bubble either just bursts completely or continues to broaden out more, conflating more things with “the trade”. If the latter happens, I see a lot of adjacent, heavily-shorted junk in genomics that probably work, at a fraction of the multiple. Those and all the fallen biotech darlings seem like strong bets from here.
Pretty interesting to dissect $ARKG performance over the past 12 months. Virtually all of its gains have come from diagnostics and AI-adjacent tools ( $TWST / $TXG / $NTRA / $PSNL ), while genomic therapeutics ($CRSP / $BEAM / $PRME) have been flat to down. I'm not complaining, I've been plenty exposed to the rally, but it's worth remembering what all these "AI is going to cure x stories" are ultimately supposed to achieve and who already has the head start plus access to the same tools...🙃
6
3
1
53
17,133
Rich is talking about that California hopefully will legislate coverage for scalp cooling in the coming weeks and here it is
1/6 Kalifornien har antagit AB 1682, en ny lag som kräver försäkringsskydd för FDA-godkänd skalpkylning för cancerpatienter. Detta kan bli en modell för andra delstater och träder i kraft 1 januari 2027. $PAX
2
455
Healthy Stock Picks retweeted
From Bernstein: AI in Drug Discovery - separating the hype from the real goals & progress
10
24
3
188
25,588
These are great, do Hong Kong, Singapore and Bangkok
1
927